Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Qiagen N.V.    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

QIAGEN : QuantiFERON®-TB Access development program gains recognition from United Nations initiative for health innovation

share with twitter share with LinkedIn share with facebook
share via e-mail
05/21/2019 | 04:08pm EDT

New breakthrough test for low-resource, high-burden regions to help in global fight against tuberculosis

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that QuantiFERON®-TB Access, a new solution under development for diagnosis of latent tuberculosis (TB) infection in low-resource regions with a high disease burden of tuberculosis, will be recognized by the Joint United Nations Programme on HIV/AIDS (UNAIDS) at the organization’s Health Innovation Exchange from May 21-23 in Geneva, Switzerland. The event will be held during the World Health Assembly and brings together ministers of health, nonprofits and industry to spotlight innovations with potential to change the world’s health landscape and benefit sustainable development.

QuantiFERON-TB Access (QFT® Access) is a proprietary new test designed to advance tuberculosis control in areas with limited infrastructure, including countries in Asia, Africa and Latin America. The World Health Organization (WHO) has classified 30 countries in these regions as high-burden, representing an estimated 85% of the global TB burden. QFT Access pairs highly sensitive digital detection with a complete workflow created to deliver cost-efficient results quickly and with unmatched simplicity. It eliminates the need for an extensive laboratory infrastructure while providing best-in-class QuantiFERON technology. Clinical trials are being conducted in 2019, and commercialization of QFT Access is expected to begin in 2020.

“We are pleased that UNAIDS selected QuantiFERON-TB Access for recognition at the Health Innovation Exchange. QIAGEN’s drive to develop QFT Access springs from the need for a modern, accurate test for TB infection screening in areas where the disease burden is high but resources and infrastructure are scarce,” said Thierry Bernard, Senior Vice President, Head of the Molecular Diagnostics Business Area at QIAGEN. “QFT Access builds on the success of QuantiFERON®-TB Gold Plus, the modern gold standard for detection of latent TB infection. We have created a field-friendly Sample to Insight solution using a simple test to reduce costs and labor and avoid the need for cold chain, a computer or continuous power supply.”

QIAGEN is developing QuantiFERON-TB Access in partnership with Ellume, an Australian developer of digitally-enabled diagnostics. QFT Access is a single visit, single tube test using 1 ml blood test that is scalable. It is not impacted by BCG vaccination, which can cause false-positive results with the tuberculin skin test used in many low-resource settings. QFT Access requires less than five minutes of hands-on time from a technician or phlebotomist. The result can be digitally displayed on a portable device or, optionally, connected to a computer for printout or electronic transmission. The system does not require maintenance or calibration, and it minimizes the impact of power loss or dust.

Please find full press release here.

###


© Business Wire 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on QIAGEN N.V.
06/04QIAGEN NV : Downgraded from Neutral to Sell by Independant Research
MD
06/02QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
05/29QIAGEN NV : DZ Bank reiterates its Neutral rating
MD
05/28QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
05/28QIAGEN : Builds on Leading Position in Precision Medicine With Novel Solutions i..
BU
05/20QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
05/19THERMO FISHER SCIENTIFIC : Publishes Offer Document for Voluntary Tender Offer f..
AQ
05/18QIAGEN N : Announces Publication of Reasoned Position Statement for Proposed Acq..
BU
05/17Coronavirus Vaccine Frontrunners Emerge, Rollouts Weighed
DJ
05/08QIAGEN N.V. : Release of a capital market information
EQ
More news
Financials (USD)
Sales 2020 1 689 M - -
Net income 2020 253 M - -
Net Debt 2020 912 M - -
P/E ratio 2020 37,3x
Yield 2020 -
Capitalization 10 130 M 10 130 M -
EV / Sales 2019
EV / Sales 2020 6,54x
Nbr of Employees 5 100
Free-Float 97,2%
Chart QIAGEN N.V.
Duration : Period :
Qiagen N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Average target price 40,42 $
Last Close Price 44,36 $
Spread / Highest target 12,7%
Spread / Average Target -8,89%
Spread / Lowest Target -30,1%
EPS Revisions
Managers
NameTitle
Thierry Bernard Chief Executive Officer
Sven Håkan Björklund Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Roland Sackers Chief Financial Officer & Managing Director
Metin Colpan Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
QIAGEN N.V.31.24%10 130
LONZA GROUP32.67%36 393
IQVIA HOLDINGS INC.-2.14%28 876
CELLTRION, INC.41.71%27 183
SEATTLE GENETICS, INC.31.66%26 040
MODERNA, INC.209.76%23 559